996 related articles for article (PubMed ID: 18336542)
1. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
2. Regulatory agencies, pharmaceutical information and the Internet: a European perspective.
Bauschke R
Health Policy; 2012 Jan; 104(1):12-8. PubMed ID: 22101089
[TBL] [Abstract][Full Text] [Related]
3. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
4. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
5. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
6. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
7. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
8. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
9. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
[TBL] [Abstract][Full Text] [Related]
10. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
11. Vigilance systems in the EU and the US: a short comparison.
van Eeckhoven E
Med Device Technol; 1994; 5(6):27-9. PubMed ID: 10172088
[TBL] [Abstract][Full Text] [Related]
12. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
Lehner JP; Meyer F; Juillet Y
Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
[TBL] [Abstract][Full Text] [Related]
13. Automated support for pharmacovigilance: a proposed system.
Bright RA; Nelson RC
Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
[TBL] [Abstract][Full Text] [Related]
14. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
Zierenberg O
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
[TBL] [Abstract][Full Text] [Related]
15. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
[TBL] [Abstract][Full Text] [Related]
16. [Orphan drugs in France (2001-2005): access to information and characteristics].
Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
[TBL] [Abstract][Full Text] [Related]
17. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
18. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
19. European biologicals registers: methodology, selected results and perspectives.
Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
[TBL] [Abstract][Full Text] [Related]
20. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
